Boehringer Enrolls Patients for Lung Cancer Study

Boehringer Ingelheim has begun enrolling subjects in a Phase III study for its lung cancer treatment BIBW 2992.

The LUX-Lung 1 study will determine the efficacy of the drug in lung cancer patients who have not responded to similar treatments such as gefitinib or erlotinib.

Data from a Phase II study of the drug showed patients with advanced non-small cell lung cancer who were treated with the drug experienced a disease control rate of 87 percent and an overall response rate of 50 percent, Boehringer said.